Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Br J Cancer
; 106(8): 1406-14, 2012 Apr 10.
Article
in En
| MEDLINE
| ID: mdl-22491422
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Glycoproteins
/
Signal Transduction
/
Drug Resistance, Neoplasm
/
Epidermal Growth Factor
/
Receptor, Fibroblast Growth Factor, Type 3
/
ErbB Receptors
/
Antibodies, Monoclonal
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Br J Cancer
Year:
2012
Document type:
Article